- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | Kairos Pharma präsentiert vielversprechende Daten zu Krebsmedikament | 1 | Investing.com Deutsch | ||
| 03.06. | Kairos Pharma presents promising cancer drug data | 1 | Investing.com | ||
| 03.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | D.Boral Capital: Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference | 97 | Newsfile | Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place... ► Artikel lesen | |
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.04. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.04. | Kairos Pharma treibt Krebsmedikamententests voran und erweitert Standorte | 2 | Investing.com Deutsch | ||
| 24.04. | Kairos Pharma advances cancer drug trials, expands sites | 2 | Investing.com | ||
| 21.04. | H.C. Wainwright maintains Buy on Kairos Pharma shares, $12 target | 1 | Investing.com | ||
| 15.04. | Kairos Pharma, LTD. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.04. | H.C. Wainwright sets $12 target for Kairos Pharma stock | 1 | Investing.com | ||
| 31.03. | Kairos Pharma treibt Phase-2-Studie für Prostatakrebs voran | 1 | Investing.com Deutsch | ||
| 31.03. | Kairos Pharma advances phase 2 trial for prostate cancer | 3 | Investing.com | ||
| 28.03. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105 | 317 | Newsfile | Toronto, Ontario--(Newsfile Corp. - March 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded... ► Artikel lesen | |
| 20.03. | Kairos Pharma meldet Durchbruch bei Lungenkrebs-Behandlung | 3 | Investing.com Deutsch | ||
| 20.03. | Kairos Pharma reports breakthrough in lung cancer treatment | 1 | Investing.com | ||
| 20.03. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.02. | Kairos Pharma reports promising preclinical cancer data | 1 | Investing.com | ||
| 26.02. | Kairos Pharma, LTD. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,740 | -2,18 % | ADMA Biologics (ADMA) Drops for 5th Consecutive Day - Here's Why | ||
| QIAGEN | 40,555 | +0,68 % | Qiagen NV-Aktie mit leichten Kursgewinnen (40,955 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Die Aktie kostete zuletzt 40,96 Euro. Ein Kursanstieg in Höhe von 0,275 Euro erfreut derzeit die Aktionäre von Qiagen NV. Aktuell kostet das Papier 40,96... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 45,870 | -1,25 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
| NUVALENT | 75,00 | -0,71 % | Nuvalent, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 10,320 | -4,36 % | Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint | WASHINGTON (dpa-AFX) - Dyne Therapeutics (DYN) announced the FDA has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of myotonic dystrophy type 1. The company also announced... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 2,610 | -5,43 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates | Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 42,340 | -1,47 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,790 | +3,01 % | Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences | ||
| EVOTEC | 6,544 | -0,37 % | Profitieren Sie vom Biotech-Boom: Warum Evotec, BioNxt Solutions & BioNTech Ihre nächsten Gewinner sein könnten. | Der Biotech-Sektor pulsiert mit einzigartiger Dynamik, während traditionelle Märkte schwächeln. Treiber sind milliardenschwere Übernahmen, bahnbrechende Forschung und strategische Allianzen. Große Pharmakonzerne... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,970 | +0,38 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,460 | -4,28 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| CARIS LIFE SCIENCES | 27,480 | -1,26 % | Caris Life Sciences Prices IPO Of About 23.53 Mln Shares At $21.00/shr | WASHINGTON (dpa-AFX) - Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23.53 million shares of its common stock at a public offering price of $21.00... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 29,275 | -0,15 % | Wolfe Research initiates Avidity Biosciences stock with outperform rating | ||
| EDGEWISE THERAPEUTICS | 14,300 | -1,17 % | Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | - Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) -
- Strengthened balance sheet with net proceeds... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,190 | -5,06 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen |
KAIROS PHARMA LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,31 % bei einem Aktienkurs von 0,645 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.